Navigation Links
CeNeRx BioPharma Completes $15 Million Series B Financing
Date:10/17/2008

- New Funds Will Support Phase II Trial of Novel Antidepressant Tyrima(TM) and Advancement of Cannabinoid Compounds -

RESEARCH TRIANGLE PARK, N.C., Oct. 17 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $15 million Series B financing. Existing investors Aisling Capital, L Capital Partners and Pappas Ventures participated in the funding round. CeNeRx plans to use the proceeds to conduct a Phase II clinical trial of its lead product candidate Tyrima(TM) for the treatment of major depressive disorder (MDD), to further characterize its novel preclinical cannabinoid pipeline and potentially to acquire additional development stage compounds targeted at CNS disorders.

"This successful Series B financing is a validation of the excellent progress we are making in advancing Tyrima, which we believe has the potential to be an important new option in the $15 billion antidepressant market," said Mark Baric, President of CeNeRx. "We appreciate the vote of confidence shown by our existing investors who all participated in the financing. These funds provide the resources we need to continue the positive momentum we have been achieving in our clinical and preclinical programs."

Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A (MAO-A). In a separate press release issued today, CeNeRx announced the initiation of a Phase II clinical trial to evaluate the antidepressant efficacy of Tyrima in patients with MDD.

"We welcome this opportunity to invest in CeNeRx's progress as it begins a Phase II trial of Tyrima, which has the potential to be the first triple-action antidepressant with a safety profile appropriate for use by the many patients inadequately served by current treatments," said Steven A. Elms, CeNeRx Board Cha
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Lilly Recognized as One of the Worlds Top Biopharmaceutical Employers
2. Millennium Ranks in the Top 10 Best Biopharma Employers in the World by Science Magazine
3. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
4. Helix Biopharma Closes $11.4 Million Private Placement
5. ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
6. Helix BioPharma Announces $11.4 Million Private Placement
7. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
8. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
9. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
10. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
11. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2009)... a division of the National Institutes of Health (NIH), awarded ... its development of a non-invasive, passive diffusion-based treatment for severe, ... ... Salt Lake City, UT (PRWEB) December 10, 2009 -- The ... of Health (NIH), awarded a $2.18 million grant to Aciont ...
(Date:12/10/2009)... United Kingdom, Dec. 10 Newly ... East England Stem Cell Institute (NESCI) in ... successful treatment of eight patients with "Limbal ... own stem cells without the need of ... http://www.newscom.com/cgi-bin/prnh/20080422/CLTU133LOGO-a ) ,, LSCD is a painful, ...
(Date:12/10/2009)... Instrument, a world-leading provider of advanced flow measurement, ... will join the company as Global Level Product ... Brooks Instrument’s efforts to enhance market penetration of ... is joining Brooks Instrument from Lafarge Corp, a ... Director of Marketing and Sales. Bayda will report ...
(Date:12/10/2009)... -- Vivakor, Inc. (OTC Bulletin Board: VIVK) ... an exclusive, $5 million license agreement with ... www.regeneca.com ). The agreement exclusively licenses ... cutting-edge nutraceutical formulation developed by Vivakor and ... by Vivakor for Regeneca. Under the terms ...
Breaking Biology Technology:NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3Successful Stem Cell Therapy for Treatment of Eye Disease 2Successful Stem Cell Therapy for Treatment of Eye Disease 3Successful Stem Cell Therapy for Treatment of Eye Disease 4Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3
... American Academy of Pediatrics National Conference & ... ... Pa., Oct. 29 Tengion,Inc., a leader in regenerative medicine, announced ... American Academy of,Pediatrics (AAP) National Conference and Exhibition demonstrate the ability,of ...
... SAN MARCOS, Calif., Oct. 29 Cliniqa ... diagnostic products, is pleased to,announce the acquisition ... "Raichem" (San Diego, CA), a wholly owned ... is a manufacturer of clinical,diagnostic products focusing ...
... Repair Discussed at American Society of Plastic Surgeons ... ... the debut of NBC,s,"Bionic Woman," the notion of a bionic person ... getting closer to reality,as reconstructive plastic surgeons perform quality-of-life-enhancing,peripheral nerve surgeries ...
Other Biology Technology:Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 2Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 3Cliniqa Corporation Completes Asset Acquisition of Reagents Applications, Inc. 2Creating the Bionic Woman: Making Nerves Spring Back to Life 2Creating the Bionic Woman: Making Nerves Spring Back to Life 3
(Date:12/11/2009)... professor of anthropology at the University of Arizona, has ... understand how violence shapes the health of those eking ... and her colleagues, research," Documenting the health consequences of ... A conceptual framework," is currently published in a special ... collaboration with the British medical journal the Lancet ...
(Date:12/11/2009)... edition of Springer,s classic reference and textbook Vogel and ... McKusick Leadership Award. The prize, which recognizes Professor Motulsky,s ... presented to him at the 59th Annual Meeting of ... 2009 in Honolulu, Hawaii. , Motulsky is Professor Emeritus ... Washington in Seattle. One of the founding giants of ...
(Date:12/11/2009)... lost a moderate amount of weight by eating less ... study at Washington University School of Medicine in St. ... in the Dec. 15, 2009, issue of the ... that weight loss led to improvement in four key ... in the study participants included decreased thickness of heart ...
Breaking Biology News(10 mins):UA-led study grapples with health effects of low-intensity warfare 2Moderate weight loss in obese people improves heart function 2Moderate weight loss in obese people improves heart function 3From the glass to the brain in 6 minutes 8835 1From the glass to the brain in 6 minutes 8835 2Hard to Treat Diseases Inc 28HTDS 29 Finalizes Agreement with Yunnan Walvax Biotech 48920 1Hard to Treat Diseases Inc 28HTDS 29 Finalizes Agreement with Yunnan Walvax Biotech 48920 2Finding Raises Hope for Treating ALS 48916 1Finding Raises Hope for Treating ALS 48916 2
... the Biomedical Engineering Society (BMES) will launch a ... (CMBE) in March 2008. Springer is already ... Biomedical Engineering. , Cellular and Molecular Bioengineering ... of cellular and molecular bioengineering, thus advancing this ...
... A consortium of researchers led by the Genome Sequencing Center ... the completion of a draft sequence of the corn genome. ... partnership with the U.S. Department of Agriculture (USDA) and the ... to sequence the corn genome. The goal of the project ...
... Dr. Peter Glynn, a professor at the University of ... been selected to receive the 2007-2008 Provosts Award for ... pursuits, and provides the recipient with a cash award ... time Glynn, who received the award when it was ...
Other Biology News:Springer expands publishing partnership with the Biomedical Engineering Society 2All eyes and ears on the corn genome 2All eyes and ears on the corn genome 3UM coral scientist Peter Glynn wins award for scholarly activity 2
BD BioCoat Laminin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
BD BioCoat Collagen I 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of rat tail collagen type I....
... is a new product number, created ... If showing no availability yet, please ... (C6671) or contact customer service for ... area 148 cm 2 Mfr ...
... This CLS number is a new ... product number. If showing no availability yet, ... (Z71,371-6) or contact customer service for assistance. ... Comp Dim: surface area 500 cm ...
Biology Products: